Physician profile
Hope Mclean
NPI 1477756468
$2,568.48
in general payments reported to CMS, 2019-2025
31 companies · $439 in 2025
The $439 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $187 · 2021: $608 · 2022: $453 · 2023: $314 · 2024: $262 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.44 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.34 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $318.77 | 2022-2025 | |
| Novo Nordisk INC | $264.96 | 2021-2024 | Wegovy |
| Organon LLC | $152.50 | 2022-2025 | Nexplanon, Jada System |
| Coopersurgical, INC. | $142.35 | 2019-2022 | |
| Pfizer INC. | $124.24 | 2019-2023 | |
| Therapeuticsmd, INC. | $103.72 | 2021-2022 | |
| Exeltis, USA INC. | $97.50 | 2019-2025 | Slynd |
| Evofem Biosciences, INC. | $84.46 | 2021-2025 | Phexxi, Solosec, Phexx |
| Aspira Women'S Health INC | $82.27 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.26 | 2019-2023 | |
| Millicent US INC | $78.69 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Shield Therapeutics INC | $75.77 | 2023-2024 | Accrufer |
| Hologic Sales and Service, LLC | $62.81 | 2021-2025 | Aptima |
| Sage Therapeutics, LLC | $53.33 | 2024-2025 | Zurzuvae |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $44.92 | 2020 | |
| Currax Pharmaceuticals LLC | $41.01 | 2022 | |
| Mylan Pharmaceuticals INC. | $39.25 | 2021-2022 | |
| Avion Pharmaceuticals | $30.82 | 2019-2023 | Balcoltra |
| Myovant Sciences INC. | $24.70 | 2022 | |
| Lupin INC. | $23.67 | 2019-2020 | |
| Medline Industries LP | $23.47 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.74 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.46 | 2025 | Qelbree |
| Zyla Life Sciences, INC. | $17.46 | 2020 | |
| Scynexis, INC. | $14.37 | 2022 | |
| Eisai INC. | $13.99 | 2020 | |
| Sumitomo Pharma America, INC. | $13.98 | 2024 | Myfembree |
| Astellas Pharma US INC | $13.96 | 2025 | Veozah |
| Amag Pharmaceuticals, INC. | $13.65 | 2019 | |
| Vivus LLC | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.